Cytokinetics Jefferies Global Healthcare Conference
Review the key takeaways and the transcript of this earnings call.
Transcript
Preview the first fifteen paragraphs, organized by speaker.
Alrighty. Getting my steps in and also risking getting hit by a cab, but that is part of the job description here. I really do appreciate it. My name's Akash Tewari. I lead our pharma and biotech research efforts here at Jefferies. I have the pleasure of hosting the Cytokinetics management team. Obviously a very important launch going on in the HCM space with MYQORZO. Robert, why don't I hand it off to you for intro remarks, and we'll get started.
Thank you. Thanks for inviting us back. Yesterday, we made an announcement that the FDA has approved our supplemental NDA, and therefore has expanded the label for MYQORZO for inclusion of results from MAPLE-HCM, a study of monotherapy MYQORZO versus monotherapy metoprolol. At this conference, we've been talking about how that's informative, and as we guided, not per se transformative. It's instead incremental, but step one towards a multi-step process to ensure that those results can be not only distinguishing aficamten from mavacamten, but more importantly, activating more physicians to be considering use of a cardiac myosin inhibitor earlier in the treatment of patients with oHCM. Until such time as the guidelines are updated, which we expect to occur both in Europe and in the U.S. next year, we think physicians will more likely be still needing to step through beta blockers, but may do so more rapidly.
That physician behavior over time will contribute to changes in how payers perceive this category. We do believe that that will be meaningfully important over the longer term to be enabling of more cardiologists, especially in the community, who follow guidelines to be more comfortable starting patients sooner, or instead of on a beta blocker. So, that's the news as it relates to yesterday's announcement and MAPLE-HCM. Put that into the context of what we've already been reporting with our Q3 earnings call recently. The MYQORZO launch is off to a very good start. We're exceeding expectations, not just in the things that relate to the obvious net sales exceeding consensus, but also the things we've pointed to in terms of breadth and depth of prescribing and category growth, all of which are meaningfully different now year-over-year for the addition of aficamten into this marketplace.
We're very encouraged by everything we're seeing towards those objectives. Lastly, we guided that we're going to be submitting this quarter the sNDA for ACACIA-HCM, and as could be enabling of the expansion of the label yet again next year to be inclusive of not only oHCM, but nHCM. That represents a potential doubling in the TAM, and where we think MYQORZO could ultimately be the leader in this space. We think that's distinguishing because MYQORZO would then be the only cardiac myosin inhibitor approved across the full spectrum of HCM obstructive and non-obstructive. So, 2026 is proving to be a very good year. We were reflecting a moment ago about how a year ago, we were being asked questions like, "Why do you have confidence that aficamten will be approved in oHCM?
Why do you think that you could be approved with a differentiated risk mitigation profile? Why do you think you can compete effectively with BMS in a market where they've already been present for four years? We think we're executing very well against all of those, and as we peer into 2027, even more ambitious plans ahead.
Understood. Let's start on the commercial side, and I know your team's very conservative, and that's just good hygiene, I would say, in general. Let's push you a bit on this, because it's funny, you had almost the identical number of days for the first quarter of MYQORZO, first quarter of CAMZYOS. I'm looking at quarter-over-quarter performance. You are 2.5 times better than where CAMZYOS was at the same time point. I know your team previously said, "Look, we hope to be better than what the CAMZYOS launch was," but that was an aspiration, but not something that we could really look and point to hard numbers on. Number two, you get MAPLE, and then we're going to get non-obstructive, and we'll talk a bit about that as well. You're already on a faster run rate in terms of patient adds.
Why would we not see patient adds accelerate over the next, let's say, year, as you get the MAPLE indication and non-obstructive put on the label? What's the right run rate to think about for MYQORZO patient adds as we get out to the end of the decade?
We talk about velocity. By definition, we do believe that there should be an acceleration of patient adds. I think more important in the medium to long term is how is this category growing?
and where is that growth coming from, and to what extent can we capture that? BMS isn't going to lie down, but I do think that BMS is investing in ways that will serve both companies well. They're activating more community cardiologists who had been previously not writing a cardiac myosin inhibitor. We're focusing, as we indicated we would, to those high-volume accounts. At one time, they represented 80% of the business, now maybe closer to 60% of the business at the present quarter. But we do think this augurs well for BMS and Cytokinetics to continue to do well and even better over time, so accelerating. To your question about, if I'm hearing you correctly, how might that contribute to something that's less linear and more asymmetric, I do think that one should be pointing to when do we really bend the curve?
I do think that could be conceivable in 2027, especially with the add of nHCM.
Right. Let's put it another way, and that's quite helpful color. It's not fun to deal with this with the twin goals of launch curves, but often cardiovascular companies will remind us, it takes some time, maybe years two to three is when we start to see an inflection. You talked about bending the curve. Do you feel like the evidence you've seen so far with the CAMZYOS launch, I mean, sorry, the MYQORZO launch, this is not like a traditional CV launch that we've seen. We are seeing uptake rapidly out of the gate, and it's at a different cadence than what maybe investor, what we saw with CAMZYOS, where it did take a couple years to really get the system wired.
Ours is next in the marketplace. It's next in class, if you will. Traditional cardiology launches, a second entrant into the category does see uptake sooner. But to the point of, is it a non-classical cardiovascular launch? I think it's too early to say that.
I think it could very well track with other cardiology launches. The nice thing about cardiology launches is there's a long tail. You saw it with Entresto, and everybody remembers how people were questioning whether Novartis was going to be able to achieve its sales guidance, and they blew through it and doubled it over time. Folks were questioning whether CAMZYOS could be a $4 billion drug at peak, and therefore, did BMS pay too much in acquiring it when they guided to $4 billion? I think they're on track to do $4 billion at peak, and I think we'll hopefully do better.
I think this is tracking like you should expect a cardiovascular launch to track.
Understood. When we think about nHCM, and you're going to have an approval decision on that from the agency sometime next year, talk to me about your confidence of the data that you did generate, in terms of, A, getting approval, but then B, it does seem like your team thinks there is a bolus, that there are patients who are waiting to get treatment. A, comments on approval, B, has your team identified patients who would immediately be seeking treatment with MYQORZO when this does get onto the market?
FULL TRANSCRIPT
Continue the full translated transcript in StockNow.
Access every statement, the English original, and speaker-by-speaker history with StockNow Pro.
View the full transcript with ProCall participants
5 people spoke on this call — only 2 are shown here.
PARTICIPANT LIST
View participant details in StockNow.
Log in to see executives and analysts, their roles, and complete speaking history.
Log in to view all participantsKeep exploring
